Myriad Genetics (NASDAQ:MYGN) Updates FY25 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $0.07-0.11 for the period, compared to the consensus EPS estimate of $0.15. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $879.47 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MYGN. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. UBS Group initiated coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price target for the company. Morgan Stanley cut their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. Bank of America decreased their target price on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research report on Friday, December 13th. Finally, Piper Sandler decreased their price objective on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $24.27.

Myriad Genetics Stock Down 4.2 %

Shares of NASDAQ MYGN opened at $13.68 on Wednesday. The business has a 50-day simple moving average of $15.05 and a two-hundred day simple moving average of $22.17. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 52 week low of $12.87 and a 52 week high of $29.30. The company has a market cap of $1.25 billion, a P/E ratio of -10.52 and a beta of 1.89.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.